Medical Innovation Exchange

ESMO: AstraZeneca’s checkpoint inhibitor bispecific may rival Keytruda, but dose change leaves questions

https://www.fiercebiotech.com/biotech/esmo-astrazenecas-ctla-4-bispecific-shows-it-can-rival-keytruda-mid-trial-dose-change

Leave a Comment

Your email address will not be published.

Leave the field below empty!